Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.43 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11265094 | 1.00 | ZDHHC7 (0.44) | ZDHHC7LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL9584643 | 0.86 | LCK (0.43) | ZDHHC7LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL28355783 | 0.81 | LCK (0.43) | ZDHHC7LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL202016 | 0.80 | LMNA (0.54) | LMNADNM1TSHRTHRBGPR84 | |
| SCHEMBL22207210 | 0.80 | LMNA (0.54) | LMNADNM1TSHRTHRBGPR84 | |
| SCHEMBL25185975 | 0.80 | LMNA (0.54) | LMNADNM1TSHRTHRBGPR84 | |
| SCHEMBL200037 | 0.80 | LMNA (0.54) | LMNADNM1TSHRTHRBGPR84 | |
| SCHEMBL22158068 | 0.80 | LMNA (0.42) | LCKPPARDZDHHC20ZDHHC2LMNA | |
| SCHEMBL22207475 | 0.80 | LMNA (0.54) | LMNADNM1TSHRTHRBGPR84 | |
| SCHEMBL5932008 | 0.80 | LMNA (0.54) | LMNADNM1TSHRTHRBGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTER E.V. (DE) | 2002-11-21 | — | — | US | disclosed |
| EP-0916343-A1 | use of alkzl phosphoric acid compounds for the treatment of psoriatic diseases | ASTA Medica Aktiengesellschaft (DE) | 1999-05-19 | — | — | EP | disclosed |
| US-5290769-A | Applying compositions for skin disorders | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1994-03-01 | — | — | US | disclosed |
| EP-0248062-B1 | MEDICAMENTS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-05-06 | — | — | EP | disclosed |
| EP-0248858-B1 | NOVEL PHOSPHO-COMPOUNDS AND MEDICAMENTS CONTAINING THESE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1990-02-28 | — | — | EP | disclosed |
| EP-0225608-A2 | Medicine | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1987-06-16 | — | — | EP | disclosed |
| EP-0224925-A2 | Phosphorous compounds and medicines containing them | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | PHOSPHO1, PLCG2, PPIP5K2 | ZDHHC7 822/4885LCK 429/4885PPARD 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.